IN8bio, Inc. (NASDAQ: INAB) has just announced very compelling positive data from a Phase 1 investigator-supported trial of INB-100 in patients with leukemia.
The company’s NB-100 treatment is highly effective in putting certain types of leukemia patients into 100% remission, even when other treatments have failed. The latest data showed that the treatment boosted a specific type of immune cell called gamma delta T cells that remained in the body for up to 180 days after treatment. This is a very important finding because the treatment is well tolerated. Promising results have been shown with regard to gamma delta T cell activity.
For the inside scoop on INAB, enter your email in the box below and subscribe to Microcapdaily.com today.
After confirming favorable results in patients who achieved a durable complete remission (CR) and considering the overall benefit/risk ratio, the investigators recommended a dose level for further trials. Decided to go with 2. The trial will be expanded at this dose level to enroll and treat more patients. Updated data from this extended trial will be presented at a medical meeting later this year and will provide further insight into the effectiveness of the treatment.
$INAB Wow, this has gone up from $1.40 fast this morning when I posted this. I’m on the sidelines now. Siniff. $2.50 to $2.60 resistance. https://t.co/DgaohD9RuR
—TheGodFatherKnows (@smantel) April 24, 2023
“We are excited 100% of evaluable dosed patients remained in morphologic CR, the first 3 high-risk AML patients with complex cytogenetics are currently alive, without relapse, 1 patients report long-term survival of up to 3 years,” said Dr. Trishna Goswami. Chief Medical Officer of IN8bio. Furthermore, “INB-100 demonstrates for the first time that allogeneic or donor-derived cell therapy expands and persists at higher levels in vivo, leading to improved survival.”
$INAB Presented new data from an investigator-initiated Phase 1 trial of INB-100 in patients with leukemia. Data presented at the 49th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting showed that 100% of his evaluable patients were treated with her INB-100… pic.twitter.com/jQ76OJK5FP
—BioPharmCatalyst (@BPharmCatalyst) April 24, 2023
A quick summary from the PR:
“INB-100 therapy has demonstrated long-lasting efficacy in treated patients, including those with high-risk acute myeloid leukemia (AML) and patients with acute lymphoblastic leukemia (ALL) who have failed four previous therapies. Achieved 100% complete remission (CR) of CAR-T.All evaluable patients are alive at the last evaluation and one patient is alive beyond 3 years.
The latest data show that the proliferation and persistence of allogeneic gamma-delta T cells continued up to 180 days after treatment, the first demonstration of this kind of response in allogeneic cell therapy.
Gr8 out of data @in8bio. Persistence, effectiveness… basically preventing termination of terminally ill patients. wonderful! ! ! $INAB https://t.co/olOWjmdf8t
— TW Research Group (@DanCarlson33) April 24, 2023
Dose level 2 was selected as the recommended phase 2 dose (RP2D) for further cohort expansion due to the generally favorable safety profile and evidence of gamma-delta T-cell expansion.
The company will host a conference call today at 10:00 am ET to discuss the latest clinical updates and data. ”
About Leukemia:
Leukemia is a type of cancer that affects the bone marrow and blood. This involves the abnormal production of white blood cells, which are responsible for fighting infections in the body. In leukemia, the bone marrow produces too many immature or abnormal white blood cells, which can crowd out healthy cells and impair the body’s ability to fight infections.
Common types include childhood and adult acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), the most common adult acute leukemia in both children and adults, and adult leukemia that does not require treatment. Includes chronic lymphocytic leukemia (CLL). Adult chronic myelogenous leukemia (CML) may have few or no symptoms for a long time until the leukemic cells become more aggressive.
$INAB A low float (8.8M) bio came out in the news this morning. Last insider buying was seen around $2.50. INB-100 treatment achieved durable 100% complete responses (CR) in treated patients, including high-risk acute myeloid leukemia (AML) and acute lymphoblastic leukemia patients. pic.twitter.com/NZX1XzF7BS
—TheGodFatherKnows (@smantel) April 24, 2023
About In8bio Inc.:
IN8bio is a biopharmaceutical company focused on developing gamma-delta T-cell therapies for cancer. Gamma delta T cells are a specialized T cell subset with unique properties, including the ability to discriminate between healthy and diseased tissue. IN8bio’s revolutionary DeltEx platform employs diverse approaches such as allogeneic (donor-derived), autologous (patient-derived), induced pluripotent stem cells (iPSCs), and genetic engineering to transform tumor cells into efficacious cells. Develop cell therapies that can specifically identify and eradicate
The company is conducting clinical trials of its lead product candidates, INB-200 for glioblastoma (a type of brain tumor) and INB-100 for leukemia (a type of blood cancer).
IN8bio has also just received IND approval in the second half of 2022 for another drug candidate, INB-400, which is focused on newly diagnosed glioblastoma. They began Phase 2 trials this year and have a broad portfolio of preclinical programs addressing multiple types of solid tumors.
As more details become available, INAB will provide updates. Be sure to subscribe to Microcapdaily to find out what’s happening at INAB.
Disclosure: I received no compensation for this article/video. MicroCap Daily is not an investment advisor. This article/video does not provide investment advice. Always do your research and make your own investment decisions or consult your local financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold any securities. This article/video is our opinion and is for informational and educational purposes only and does not constitute investment advice. Past performance is not indicative of future performance.
Image by Satheesh Sankaran from Pixabay